Matches in SemOpenAlex for { <https://semopenalex.org/work/W38862450> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W38862450 endingPage "9" @default.
- W38862450 startingPage "362" @default.
- W38862450 abstract "Conventional treatments such as surgery and radiotherapy for deeply invasive, clinically non-metastatic bladder cancer are associated with cure in less than 30% of cases. This has led to the search for new approaches to therapy. Based on the excellent results with combination chemotherapy such as M-VAC in patients with advanced disease, neoadjuvant or adjuvant chemotherapy has been advocated to improve survival. Twenty patients with primary invasive bladder cancer who underwent radical cystectomy received postoperative adjuvant chemotherapy using a CAP (cyclophosphamide, doxorubicin and cisplatin) or modified M-VAC (methotrexate, vinblastine, pirarubicin and cisplatin) regimen. Sixteen of the patients were treated with CAP and four with the modified M-VAC. Of the 20 patients, 17 had transitional cell carcinoma with or without non-transitional cell elements. All of the patients had tumors with a histological grade of G2 (six cases) or G3 (14 cases). As for lymph node metastasis, there were 10 N0 cases, three N1 cases, six N2 cases, and one N3 case. The five-year survival rate of these 20 patients was 65.9%, while that of 49 patients not administered any adjuvant chemotherapy was 29.9%. Regarding toxicity, both adjuvant chemotherapy regimens in this study were generally well tolerated. The most common toxic effects were gastrointestinal symptoms, alopecia and myelosuppression. Twenty other patients with invasive transitional cell carcinoma of the bladder received two or three cycles of neoadjuvant chemotherapy using the modified M-VAC or MEC (methotrexate, epirubicin and cisplatin) regimen prior to radical cystectomy or partial cystectomy. Of 19 evaluable patients who received neoadjuvant chemotherapy, a complete response was observed in two (10%), a partial response in 11 (55%), and no change in six (30%). The overall response rate was 65%. The five-year survival rate of 20 patients who received neoadjuvant chemotherapy was 74.2%. Regarding toxicity, one patient died of a bowel complication after surgery, and the complication was suggested to be drug-induced." @default.
- W38862450 created "2016-06-24" @default.
- W38862450 creator A5014449911 @default.
- W38862450 creator A5043265594 @default.
- W38862450 date "1994-10-01" @default.
- W38862450 modified "2023-09-23" @default.
- W38862450 title "[Neoadjuvant and adjuvant chemotherapy of bladder cancer]." @default.
- W38862450 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7986116" @default.
- W38862450 hasPublicationYear "1994" @default.
- W38862450 type Work @default.
- W38862450 sameAs 38862450 @default.
- W38862450 citedByCount "1" @default.
- W38862450 countsByYear W388624502020 @default.
- W38862450 crossrefType "journal-article" @default.
- W38862450 hasAuthorship W38862450A5014449911 @default.
- W38862450 hasAuthorship W38862450A5043265594 @default.
- W38862450 hasConcept C121608353 @default.
- W38862450 hasConcept C126322002 @default.
- W38862450 hasConcept C126894567 @default.
- W38862450 hasConcept C141071460 @default.
- W38862450 hasConcept C143998085 @default.
- W38862450 hasConcept C2775910329 @default.
- W38862450 hasConcept C2776085618 @default.
- W38862450 hasConcept C2776694085 @default.
- W38862450 hasConcept C2776755627 @default.
- W38862450 hasConcept C2777132456 @default.
- W38862450 hasConcept C2778065480 @default.
- W38862450 hasConcept C2778239845 @default.
- W38862450 hasConcept C2780352672 @default.
- W38862450 hasConcept C2780835546 @default.
- W38862450 hasConcept C2781413609 @default.
- W38862450 hasConcept C71924100 @default.
- W38862450 hasConceptScore W38862450C121608353 @default.
- W38862450 hasConceptScore W38862450C126322002 @default.
- W38862450 hasConceptScore W38862450C126894567 @default.
- W38862450 hasConceptScore W38862450C141071460 @default.
- W38862450 hasConceptScore W38862450C143998085 @default.
- W38862450 hasConceptScore W38862450C2775910329 @default.
- W38862450 hasConceptScore W38862450C2776085618 @default.
- W38862450 hasConceptScore W38862450C2776694085 @default.
- W38862450 hasConceptScore W38862450C2776755627 @default.
- W38862450 hasConceptScore W38862450C2777132456 @default.
- W38862450 hasConceptScore W38862450C2778065480 @default.
- W38862450 hasConceptScore W38862450C2778239845 @default.
- W38862450 hasConceptScore W38862450C2780352672 @default.
- W38862450 hasConceptScore W38862450C2780835546 @default.
- W38862450 hasConceptScore W38862450C2781413609 @default.
- W38862450 hasConceptScore W38862450C71924100 @default.
- W38862450 hasLocation W388624501 @default.
- W38862450 hasOpenAccess W38862450 @default.
- W38862450 hasPrimaryLocation W388624501 @default.
- W38862450 hasRelatedWork W1156158869 @default.
- W38862450 hasRelatedWork W2008346828 @default.
- W38862450 hasRelatedWork W2044723401 @default.
- W38862450 hasRelatedWork W2045948475 @default.
- W38862450 hasRelatedWork W2092845422 @default.
- W38862450 hasRelatedWork W2111872029 @default.
- W38862450 hasRelatedWork W2152418443 @default.
- W38862450 hasRelatedWork W236062716 @default.
- W38862450 hasRelatedWork W2398135534 @default.
- W38862450 hasRelatedWork W2602468646 @default.
- W38862450 hasVolume "21 Suppl 3" @default.
- W38862450 isParatext "false" @default.
- W38862450 isRetracted "false" @default.
- W38862450 magId "38862450" @default.
- W38862450 workType "article" @default.